论文部分内容阅读
一些免疫增强剂,在体内可诱导或激活磷酸脂酶 A,使细胞卵磷脂和磷脂酰乙醇胺降价,导致体内溶血磷脂浓度增高。据此,Munder等设想溶血磷脂的积聚,可能是宿主防御机制的内源性要素。后来发现2-溶血卵磷脂(2-LPC)是高效免疫增强剂。然而2-LPC 在体内迅速被溶血磷脂酶和2-LPC 酰基转移酶所分解。人工合成的烃化溶血磷脂类药物则不受这些酶所代谢,半衰期较长。国外已在实验研究的基础上试用于临床。本文就有关进展作
Some immune enhancers, in vivo can induce or activate phospholipase A, the cell lecithin and phosphatidylethanolamine price, resulting in increased concentrations of lysophospholipids in the body. Accordingly, Munder et al. Envisioned that the accumulation of lysophospholipids may be an endogenous factor in the host defense mechanism. It was later found that 2-lysophosphatidylcholine (2-LPC) is an effective immunopotentiator. However, 2-LPC is rapidly degraded by lysophospholipase and 2-LPC acylase in vivo. Synthetic hydrocarbon lysophospholipids are not metabolized by these enzymes and have a longer half-life. Abroad has been experimentally used in clinical trials. This article on the progress made